| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.21 | 3e-11 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.22 | 3e-10 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.21 | 1e-09 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-09 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-09 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-09 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.29 | 4e-09 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-09 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.18 | 9e-09 |